EU Life Sciences Strategy: Paving the Way for Europe’s Leadership by 2030

By João L. Carapinha

July 3, 2025

The European Commission has launched a comprehensive strategy aimed at positioning the EU Life Sciences Strategy as the world’s most attractive and competitive hub for life sciences by 2030. This initiative addresses key challenges in health, biotechnologies, agri-food, and industrial sustainabil...
Ticagrelor Data Integrity Under Fire: Scrutiny Reveals Flaws in Key Clinical Trials
A recent BMJ investigation exposes serious doubts regarding ticagrelor data integrity in pivotal studies that contributed to the approval and widespread use of AstraZeneca's antiplatelet drug ticagrelor (marketed as Brilinta or Brilique). The article reveals significant misreporting and missing d...
The Value of Self-Care in Public Health: Insights and Implications for Europe

By Rene Pretorius

July 2, 2025

Summary Self-care in public health is a critical pillar of public health in Europe. It enables individuals to manage minor ailments independently while easing pressure on healthcare systems....
Pharma Ad Spending Trends: Insights from the Top 10 Drug Advertisers of 2024
Pharma ad spending trends in 2024 indicate a significant pivot toward aggressive direct-to-consumer (DTC) marketing, with leading drug brands amplifying budgets to stay visible in an AI-powered research landscape. Which pharma companies are investing the most, and how does this shift affect healt...
Dutch Health Disruption: Reimagining Care with Social Entrepreneurship

By João L. Carapinha

July 1, 2025

The Dutch Health Disruption is a pressing issue that Michel van Schaik, Director of Healthcare at Rabobank, addresses in the June 2025 issue of Zorginstituut Magazine. He argues that the Dutch health system is fundamentally unsustainable due to escalating healthcare costs, chronic workforce short...
Pharmaceutical Industry Europe: Key Insights and Future Challenges for 2025
The pharmaceutical industry Europe continues to be a critical engine for innovation and health, driving advancements that benefit patients, economies, and scientific progress across the region. How does the European pharmaceutical sector shape global health outcomes, and what challenges does it f...

Search By Category

Latest

EU Life Sciences Strategy: Paving the Way for Europe’s Leadership by 2030

By João L. Carapinha

July 3, 2025

The European Commission has launched a comprehensive strategy aimed at positioning the EU Life Sciences Strategy as the world’s most attractive and competitive hub for life sciences by 2030. This initiative addresses key challenges in health, biotechnologies, agri-food, and industrial sustainabil...

Latest

Ticagrelor Data Integrity Under Fire: Scrutiny Reveals Flaws in Key Clinical Trials
A recent BMJ investigation exposes serious doubts regarding ticagrelor data integrity in pivotal studies that contributed to the approval and widespread use of AstraZeneca's antiplatelet drug ticagrelor (marketed as Brilinta or Brilique). The article reveals significant misreporting and missing d...

Latest

The Value of Self-Care in Public Health: Insights and Implications for Europe

By Rene Pretorius

July 2, 2025

Summary Self-care in public health is a critical pillar of public health in Europe. It enables individuals to manage minor ailments independently while easing pressure on healthcare systems....

Latest

Pharma Ad Spending Trends: Insights from the Top 10 Drug Advertisers of 2024
Pharma ad spending trends in 2024 indicate a significant pivot toward aggressive direct-to-consumer (DTC) marketing, with leading drug brands amplifying budgets to stay visible in an AI-powered research landscape. Which pharma companies are investing the most, and how does this shift affect healt...

Global Updates

DALY Modeling Methods for Enhanced Health Economics and Policy Analysis

By Staff Writer

June 24, 2025

How can DALY modeling methods enhance health policy and economic evaluation? DALY modeling methods (Disability-Adjusted Life-Year estimation techniques) are central to health economics. They empower analysts and policymakers to quantify disease burden, compare interventions, a...

Global Updates

Pharmaceutical Pricing Issues: Beyond Overpricing and Profit Motives
The BMJ article "The drug industry’s crimes and misdemeanours extend far beyond overpricing in the US" sharply critiques pharmaceutical pricing issues, arguing that profit-driven motives dominate. The discussion highlights recent decisions by the UK's NICE to deny coverage for costly

Global Updates

KEYTRUDA Head Neck Cancer Approval: Transforming Treatment and Health Economics

By João L. Carapinha

June 16, 2025

The U.S. Food and Drug Administration (FDA) has recently approved KEYTRUDA (pembrolizumab) for use in treating patients with PD-L1-positive, resectable, locally advanced head and neck squamous cell carcinoma (HNSCC). This landmark approval authorizes the use of

Global Updates

Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implications

By João L. Carapinha

June 13, 2025

The United States Food and Drug Administration (FDA) has approved an expanded indication for AbbVie’s Mavyret acute hepatitis C (glecaprevir/pibrentasvir). This makes it the first and only treatment specifically authorized for individuals with acute hepatitis C virus (HCV) infection. The approval...

Europe

EU Life Sciences Strategy
         

EU Life Sciences Strategy: Paving the Way for Europe’s Leadership by 2030

🚀 Is Europe poised to reclaim its leadership in life sciences by 2030?

The European Commission has unveiled a game-changing strategy aimed at transforming the EU into the world’s leading hub for life sciences, tackling critical challenges in health, biotechnology, and sustainability. With strategic investments and reforms, this initiative promises to bridge the innovation gap and enhance public health outcomes across the continent.

Curious about how these plans will impact the life sciences landscape? Explore the full insights of this exciting strategy!

#SyenzaNews #HealthcareInnovation #DigitalTransformation #Innovation

Middle East

publication delays impact careers
     

Publication Delays Impact Careers of Early-Career Researchers

🚨 Publication delays are derailing academic careers!

In an insightful piece, “Dear editors, your publication delays are damaging our careers,” Chia-Hsuan Hsu reveals how prolonged editorial and peer-review processes are stifling early-career researchers, particularly in East Asia. With a focus on the systemic inefficiencies in academic publishing, the article discusses the urgent need for reform to protect researchers from the detrimental impacts of such delays.

Jump into the full article to uncover the challenges faced and explore proactive solutions for a more efficient publishing landscape. 📚✨

#SyenzaNews #HealthEconomics #HealthcarePolicy

Sub-Saharan Africa

private health funding
    

Private Health Funding Under South Africa’s National Health Insurance Act

🚀 Update on NHI in South Africa.

In their insightful article, Solanki et al. discuss the complexities of private health funding amidst the nation’s National Health Insurance Act. They discuss two key scenarios: a passive approach that risks the sustainability of the private sector and an active reform strategy that could ensure a smoother transition to universal coverage.

Curious about how these strategies could reshape healthcare access and costs in South Africa? Don’t miss out on this critical analysis!

#SyenzaNews #HealthEconomics #HealthcarePolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.